BioSpace News Archive

Rabbis, clergy, imams and other leaders of faith across the state will join forces with Donate Life New York State, along with other state, national and local organizations to raise awareness about the need for organ donors during National Donor Sabbath Weekend, which takes place on Nov. 9-11.

HealthLytix, a precision health company and developer of quantitative medical imaging solutions that leverage machine learning announces the release of CT CoPilot™ at the upcoming Radiological Society of North America (RSNA) 2018 annual meeting in Chicago.

A new collaboration between ODLO, Clim8 and Twinery provides an intelligent heating performance midlayer that gives people zero excuses not to enjoy their winter activities

Technavio analysts forecast the global wound therapy devices market to grow at a CAGR of over 7% during the forecast period, according to their latest market research report.

The Medicines Company is a biopharmaceutical company driven by an overriding purpose – to save lives, alleviate suffering and contribute to the economics of healthcare.

SAN FRANCISCO, /PRNewswire/ -- The utility of imaging biomarkers in NASH is the focus of several abstracts accepted for presentation, here, at the American Association for the Study of Liver Disease’s The Liver Meeting® 2018, November 9-13, 2018 (Booth #611).

Today, the Food and Drug Administration (FDA) announced that an emergency use authorization (EUA) has been issued for a rapid, single-use test for the detection of Ebola virus (Zaire ebolavirus).

Technavio analysts forecast the global urinary incontinence therapeutics market to grow at a CAGR of over 3% during the forecast period, according to their latest market research report.

The Delta Dental Community Care Foundation announced today that it awarded The University of Texas Health Science Center at Houston (UTHealth) School of Dentistry a $160,000 grant to support the school’s annual Give Kids a Smile and Give Vets a Smile events, with additional support for continued treatment of veterans through the program.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preliminary clinical data from a Phase 1/2 study (AROHBV1001) of ARO-HBV, a third-generation subcutaneously administered RNA interference (RNAi) therapeutic candidate being developed as a potential treatment for patients with chronic hepatitis B virus (HBV) infection.